Assessment of sequence-based p53 gene analysis in human breast cancer: Messenger RNA in comparison with genomic DNA targets

Clinical Chemistry

Volumn 44, Issue 3, 1998, Pages 455-462

  Williams, Cecilia ^a   Norberg, Torbjörn ^b   Ahmadian, Afshin ^a   Pontén, Fredrik ^c   Bergh, Jonas ^c   Ingan̈as, Mats ^b   Lundeberg, Joakim ^a   Uhlén, Mathias ^a  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b GE Healthcare Bio Sciences AB   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN P53;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; DNA DETERMINATION; DNA RNA HYBRIDIZATION; DNA SEQUENCE; DNA TEMPLATE; GENE TARGETING; HUMAN; HUMAN TISSUE; MISSENSE MUTATION; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

EID: 0031912860     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.3.455     Document Type: Article

References (30)

1. Davidoff AM, Kerns BJM, Iglehart JD, Marks JR. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 1991;51:2605-10.
2. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
3. Coles C, Thompson AM, Elder PA, Cohen BB, Mackenzie IM, Cranston G, et al. Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis. Lancet 1990;336: 761-3.
4. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A 1991;88:5006-10.
5. Singh S, Simon M, Meybohm I, Jantke I, Jonat W, Maass H, Goedde HW. Human breast cancer: frequent p53 allele loss and protein overexpression. Hum Genet 1993;90:635-40.
6. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-6.
7. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
8. Isola J, Visakorp T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992;84:1109-14.
9. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-9.
10. Dowell, SP, Hall PA. The clinical relevance of the p53 tumour suppressor gene. Cytopathology 1994;5:133-45.
11. Lane DP. p53 human cancers. Br Med Bull 1994;50:582-99.
12. Healy E, Reynolds NJ, Smith MD, Campbell C, Farr PM, Rees JL. Dissociation of erythema and p53 protein expression in human skin following UVB irradiation, and induction of p53 protein and mRNA following application of skin irritants. J Invest Dermatol 1994;103:493-9.
13. MacGeoch C, Turner G, Bobrow LG, Barnes DM, Bishop DT, Spurr NK. Heterogeneity in Li-Fraumeni families: p53 mutation analysis and immunohistochemical staining. J Med Genet 1995;32:186-90.
14. Jansson T, Inganäs M, Sjögren S, Norberg T, Lindgren A, Holmberg L, Bergh J. p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 1995;13:2745-51.
15. Sjögren S, Inganäs M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996;88:173-82.
16. Borresen AL, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, et al. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 1995;14: 71-5.
17. Berg C, Hedrum A, Holmberg A, Pontén F, Uhlén M, Lundeberg J. Direct solid-phase sequence analysis of the human p53 gene by use of multiplex polymerase chain reaction and α-thiotriphosphate nucleotides. Clin Chem 1995;41:1461-6.
18. Gumerlock PH, Chi S-G, Shi X-B, Voeller HJ, Jacobson JW, Gelmann EP, et al. p53 abnormalities in primary prostate cancer: single-strand conformation analysis of complementary DNA in comparison with genomic DNA. J Natl Cancer Inst 1997;89:66-70.
19. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant therapy and radiotherapy. Nat Med 1995;1:1029-34.
20. Hedrum A, Pontén F, Ren ZP, Lundeberg J, Pontén J, Uhlén M. Sequence-based analysis of the human p53 gene based on microdissection of tumor biopsy samples. Biotechniques 1994; 17:118-29.
21. Chevillard S. A method for sequential extraction of RNA and DNA from the same sample, specially designed for a limited supply of biological material. Biotechniques 1993;15:22-4.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
23. Pontén F, Berg C, Ahmadian A, Nistér M, Lundeberg J, Uhlén M, Pontén J. Molecular pathology in basal cell cancer with p53 as a genetic marker. Oncogene 1997;15:1059-67.
24. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet 1992;90:41-54.
25. Leitner T, Halapi E, Scarlatti G, Rossi P, Albert J, Fenyö EM, Uhlén M. Analysis of heterogenous viral populations by direct DNA sequencing. BioTechniques 1993;15:120-6.
26. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry?-Revisited! [Editorial]. J Pathol 1994;172:1-4.
27. Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, et al. p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer 1992;50:528-32.
28. Frebourg T, Sadelain M, Ng YS, Kassel J, Friend SH. Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer Res 1994;54:878-81.
29. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
30. Zhang S, Ruiz-Echevarria MJ, Quan Y, Peltz SW. Identification and characterization of a sequence motif involved in nonsense-mediated mRNA decay. Mol Cell Biol 1995;15:2231-44.